Yahoo Finance

Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ITOS:

• iTeos Therapeutics price target lowered to $21 from $46 at H.C. Wainwright

• iTeos Therapeutics presents interim A2A-005 clinical trial data

• iTeos Therapeutics Reports Q3 2024 Financial Results

• iTeos Therapeutics reports Q3 EPS ($1.05), consensus (89c)

• Officina Stellare Secures €1.4 Million Satellite Contract